Highlights of This Issue 1819

SPECIAL FEATURES

CCR Translations

1821 The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime? 
Michael A. Postow, Margaret K. Callahan, and Jedd D. Wolchok
See article p. 2039

CCR New Strategies

1830 New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy 
Mingdong, Alexandra T. Phan, and James C. Yao
See article p. 2056

Statistics in Clinical Cancer Research

1837 Statistical Issues and Recommendations for Noninferiority Trials in Oncology: A Systematic Review 
Shiro Tanaka, Yousuke Kinjo, Yoshiki Kataoka, Kenichi Yoshimura, and Satoshi Teramukai

CCR Drug Updates

1848 Abiraterone in Prostate Cancer: A New Angle to an Old Problem 
Mark N. Stein, Susan Goodin, and Robert S. DiPaola
See article p. 2090

Molecular Pathways

1855 Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer 
A. Nigel Brooks, Elaine Kilgour, and Paul D. Smith
See article p. 2090

HUMAN CANCER BIOLOGY

1863 Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance 
Kevin G. Chen and Branimir I. Sikic

1870 Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors 
Carlo Visco, Francesco Maura, Giacomo Tuana, Luca Agnelli, Marta Lionetti, Sonia Fabris, Elisabetta Novella, Ilaria Giaretta, Gianluigi Reda, Wilma Barcellini, Luca Baldini, Antonino Neri, Francesco Rodeghiero, and Agostino Corteletti

1879 MAPKAP Kinase 2 Overexpression Influences Prognosis in Gastrointestinal Stromal Tumors and Associates with Copy Number Variations on Chromosome 1 and Expression of p38 MAP Kinase and ET1 
Peter Birner, Andrea Beer, Ursula Vinatzer, Susanne Stary, Romana Höflerberger, Nadine Nirtl, Fritz Wrbka, Berthold Streubel, and Sebastian F. Schoppmann

1901 Glioblastoma Stem-like Cell Lines with Either Maintenance or Loss of High-Level EGFR Amplification, Generated via Modulation of Ligand Concentration 
Alexander Schulte, Hauke S. Günther, Tobias Martens, Svenja Zapf, Sabine Riethdorf, Clemens Wülfling, Malgorzata Stoupiec, Manfred Westphal, and Katrin Lamszus
<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1936</td>
<td>Integrative Genomics Identified RFC3 As an Amplified Candidate Oncogene in Esophageal Adenocarcinoma</td>
<td>William W. Lockwood, Kelsie L. Thu, Lin Lin, Larissa A. Pikor, Raj Chari, Wan L. Lam, and David G. Beer</td>
</tr>
<tr>
<td>1947</td>
<td>Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis</td>
<td>Yang Zhang, Yihua Sun, Yunjian Pan, Chenguang Li, Lei Shen, Yuan Li, Xiaoyang Luo, Ting Ye, Rui Wang, Haichuan Hu, Hang Li, Lei Wang, William Pao, and Haiquan Chen</td>
</tr>
<tr>
<td>1979</td>
<td>ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress</td>
<td>Colby M. Chapman, Xiameng Sun, Mark Roschewski, Georg Aue, Mohamed Farooqui, Lawrence Stennett, Federica Gibellini, Diane Arthur, Patricia Pérez-Galán, and Adrian Wiestner</td>
</tr>
</tbody>
</table>

**IMAGING, DIAGNOSIS, PROGNOSIS**

- Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer: Alain Mangé, Jérôme Lacombe, Caroline Bascoul-Mollevi, Marga Jarlier, Pierre-Jean Lamy, Philippe Rouanet, Thierry Maudelonde, and Jérôme Solassol

- Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), Société Française d’Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP): John-Paul Kilday, Biswaroop Mitra, Caroline Domeng, Jennifer Ward, Felipe Andreiuolo, Teresa Ostens-Ibanez, Audrey Mauguen, Pascale Varlet, Marie-Cécile Le Deley, James Lowe, David W. Ellison, Richard J. Gilbertson, Beth Coyle, Jacques Grill, and Richard G. Grundy

**CANCER THERAPY: PRECLINICAL**


- Cyclin-Dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor α and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells: Yongbin Wu, Chun Chen, Xiaoyong Sun, Xianping Shi, Bei Jin, Ke Ding, Sai-Ching Jim Yeung, and Jingxuan Pan

A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration

Xavier M. Keutgen, Filippo Filicori, Michael J. Crowley, Yongchun Wang, Theresa Scognamiglio, Rana Hoda, Daniel Buitrago, David Cooper, Martha A. Zeiger, Rasa Zarnegar, Olivier Elemento, and Thomas J. Fahey III

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intrahepatic Oncolytic Reovirus in Patients with Advanced Malignancies

Eleni M. Karapanagiotou, Victoria Roulstone, Katie Twigger, Merced Ball, MaryAnne Tanay, Chris Nutting, Kate Newbold, Martin E. Gore, James Larkin, Konstantinos N. Syrigos, Matt Coffey, Brad Thompson, Karl Mettenger, Richard G. Vile, Hardev S. Pandha, Geoff D. Hall, Alan A. Melcher, John Chester, and Kevin J. Harrington

CANCER THERAPY: CLINICAL

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

Peter A. Prieto, James C. Yang, Richard M. Sherry, Marybeth S. Hughes, Udai S. Kammula, Donald E. White, Catherine L. Levy, Steven A. Rosenberg, and Giao Q. Phan

See commentary p. 1821

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

Wen Wee Ma, Wells A. Messersmith, Grace K. Dy, Colin D. Weeke, Amy Whitworth, Chen Ren, Manoj Maniar, Francois Wilhelm, S. Gail Eckhardt, Alex A. Adjei, and Antonio Jimeno

Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements


See commentary p. 1827

Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer

Michael Milosevic, Padraig Warde, Cynthia Ménard, Peter Chung, Ants Toi, Adrian Ishkanian, Michael McLean, Melanie Pintilie, Jenna Sykes, Mary Gospodarowicz, Charles Catton, Richard P. Hill, and Robert Bristow

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the γ-Secretase Inhibitor RO4929097

Jiunn-Mei Wu, Patricia M. LoRusso, Larry H. Matherly, and Jing Li

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia


CORRECTIONS

Correction: Molecular Imaging of TGFβ-Induced Smad2/3 Phosphorylation Reveals a Role for Receptor Tyrosine Kinases in Modulating TGFβ Signaling

The Journal of Clinical and Translational Research v www.aacrjournals.org

www.aacrijournals.org
ABOUT THE COVER

High-level EGFR gene amplification can be retained in glioblastoma stem-like cell lines established and propagated without recombinant EGF. In contrast, high-level amplification is lost in parallel cell lines from the same tumors established with EGF supplementation. Cell lines with high-level EGFR amplification produce highly aggressive xenograft tumors in the brains of nude mice, retaining the EGFR amplification as shown in the cover figure, whereas counterpart cell lines, lacking high-level amplification, are either nontumorigenic or grow significantly more slowly in vivo. For details, see the article by Schulte and colleagues on page 1901 of this issue.
Clinical Cancer Research

18 (7)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/18/7

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.